Compare APRE & ULY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APRE | ULY |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3M | 5.5M |
| IPO Year | 2019 | N/A |
| Metric | APRE | ULY |
|---|---|---|
| Price | $0.84 | $2.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $5.00 | ★ $11.50 |
| AVG Volume (30 Days) | 77.0K | ★ 1.5M |
| Earning Date | 11-12-2025 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $488,239.00 | ★ $127,932,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.83 | $1.74 |
| 52 Week High | $4.65 | $17.99 |
| Indicator | APRE | ULY |
|---|---|---|
| Relative Strength Index (RSI) | 33.19 | 46.53 |
| Support Level | $0.89 | $2.12 |
| Resistance Level | $0.91 | $2.75 |
| Average True Range (ATR) | 0.07 | 0.35 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 0.99 | 15.13 |
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
Urgently Inc is a connected mobility assistance software platform, matching vehicle owners and operators with service professionals who deliver traditional roadside assistance, proactive maintenance and repair services. The traditional experience of a vehicle breakdown is often stressful and inconvenient, compounded by processes that lack transparency and to long wait times. Urgently offers an alternative to this traditional experience, leveraging its digitally native software platform to match supply and demand in its network and deliver exceptional mobility assistance experiences at scale.